Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent
of patients don't respond to current treatments. MBS2320, the drug being tested in this
trial, represents a new approach to treating RA, with the potential not only to reduce levels
of inflammation but to also directly inhibit bone damage.The aim of this study is to test the
safety of MBS2320 in healthy volunteers, to find out how MBS2320 levels change in the blood
with dose, and to test the safety and compatibility of giving MBS2320 to patients with RA in
combination with an existing treatment, methotrexate.